These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 11128567

  • 41. Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.
    Cleri LB, Kris MG, Tyson LB, Pisters KM, Clark RA, Gralla RJ.
    Cancer; 1995 Sep 01; 76(5):774-8. PubMed ID: 8625179
    [Abstract] [Full Text] [Related]

  • 42. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
    Sabbatini R, Federico M, Baldini L, Barbieri F, Maiolo MT, Silingardi V.
    Haematologica; 1995 Sep 01; 80(5):416-20. PubMed ID: 8566881
    [Abstract] [Full Text] [Related]

  • 43. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
    Sawaguchi K, Yabushita H, Tsukada H, Yamada H, Noguchi M, Nakanishi M.
    Gan To Kagaku Ryoho; 1999 Jan 01; 26(1):117-23. PubMed ID: 9987507
    [Abstract] [Full Text] [Related]

  • 44. Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
    Dick GS, Meller ST, Pinkerton CR.
    Arch Dis Child; 1995 Sep 01; 73(3):243-5. PubMed ID: 7492164
    [Abstract] [Full Text] [Related]

  • 45. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
    Mantovani G, Curreli L, Macciò A, Massa E, Massa D, Mulas C, Succu G, Contu P.
    Anticancer Res; 1999 Sep 01; 19(4C):3495-502. PubMed ID: 10629642
    [Abstract] [Full Text] [Related]

  • 46. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
    Italian Group For Antiemetic Research.
    J Clin Oncol; 2004 Feb 15; 22(4):725-9. PubMed ID: 14966097
    [Abstract] [Full Text] [Related]

  • 47. [Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
    Hebbar M, Hecquet B, Vanlemmens L, Lecomte S, Pion JM, Adenis A, Bonneterre J.
    Bull Cancer; 1995 Jan 15; 82(1):67-9. PubMed ID: 7742620
    [Abstract] [Full Text] [Related]

  • 48. [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
    Zeng WY.
    Zhonghua Zhong Liu Za Zhi; 1993 Mar 15; 15(2):118-21. PubMed ID: 8223120
    [Abstract] [Full Text] [Related]

  • 49. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
    Beck TM.
    Semin Oncol; 1992 Dec 15; 19(6 Suppl 15):20-5. PubMed ID: 1485178
    [Abstract] [Full Text] [Related]

  • 50. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
    Plosker GL, Milne RJ.
    Pharmacoeconomics; 1992 Oct 15; 2(4):285-304. PubMed ID: 10147044
    [Abstract] [Full Text] [Related]

  • 51. Oral treatment with ondansetron in an outpatient setting.
    Dicato MA.
    Eur J Cancer; 1991 Oct 15; 27 Suppl 1():S18-9; discussion S22. PubMed ID: 1831630
    [Abstract] [Full Text] [Related]

  • 52. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct 15; 63(10):729-36. PubMed ID: 11076429
    [Abstract] [Full Text] [Related]

  • 53. Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.
    Shivaprakash G, Udupa KS, Sarayu V, Thomas J, Gupta V, Pallavi LC, Pemminati S.
    Indian J Pharmacol; 2017 Oct 15; 49(6):451-457. PubMed ID: 29674800
    [Abstract] [Full Text] [Related]

  • 54. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX, Hoffman IS, Fuenmayor NT, Finn AL.
    J Clin Oncol; 1990 Oct 15; 8(10):1721-7. PubMed ID: 2145400
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
    Fanning J, Hilgers RD.
    Obstet Gynecol; 1994 Apr 15; 83(4):601-4. PubMed ID: 8134073
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
    Cubeddu LX, Pendergrass K, Ryan T, York M, Burton G, Meshad M, Galvin D, Ciociola AA.
    Am J Clin Oncol; 1994 Apr 15; 17(2):137-46. PubMed ID: 8141105
    [Abstract] [Full Text] [Related]

  • 60. Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.
    Campora E, Oliva C, Mammoliti S, Cetto GL, Fosser V, Marangolo M, Rosso R.
    Breast Cancer Res Treat; 1991 Oct 15; 19(2):129-32. PubMed ID: 1836746
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.